Burnett A K, Eden O B
Department of Haematology, University of Wales College of Medicine, Cardiff, UK.
Lancet. 1997 Jan 25;349(9047):270-5. doi: 10.1016/s0140-6736(96)08086-5.
Developments in supportive care, new regimens for induction of remission and consolidation therapy, and bone-marrow transplantation have improved the outlook for patients with acute leukaemia. The outlook, though, is influenced by age and factors related to the biology of the disease. In acute myeloid leukaemia age is such an important factor that it determines approach to therapy. Overcoming resistance to chemotherapy is an area that needs much attention.
支持性护理的进展、诱导缓解和巩固治疗的新方案以及骨髓移植改善了急性白血病患者的预后。然而，预后受年龄和与疾病生物学相关因素的影响。在急性髓系白血病中，年龄是一个非常重要的因素，它决定了治疗方法。克服化疗耐药性是一个需要高度关注的领域。
